Late doxorubicin cardiotoxicity

M. Lishner*, A. Elis, M. Ravid

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The occurrence of late congestive heart failure (CHF) as the first clinical manifestation of doxorubicin-induced cardiac toxicity is unusual in children and very rare in adults. However, subclinical cardiac dysfunction is commonly detected in children years after treatment with doxorubicin containing regimens. We report a 58 year old woman who developed stage IV CHF 7 years after completion of doxorubicin treatment for carcinoma of the ovary. Occult cardiac dysfunction was first demonstrated by radionuclide angiography 6 years prior to the occurrence of the clinical manifestations. This unique course of the disease and the management of the CHF are discussed.

Original languageEnglish
Pages (from-to)367-369
Number of pages3
JournalAnti-Cancer Drugs
Issue number4
StatePublished - 1992


Dive into the research topics of 'Late doxorubicin cardiotoxicity'. Together they form a unique fingerprint.

Cite this